+

WO2001075064A3 - Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline - Google Patents

Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline Download PDF

Info

Publication number
WO2001075064A3
WO2001075064A3 PCT/US2001/010462 US0110462W WO0175064A3 WO 2001075064 A3 WO2001075064 A3 WO 2001075064A3 US 0110462 W US0110462 W US 0110462W WO 0175064 A3 WO0175064 A3 WO 0175064A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
polynucleotides
insulin
growth factor
binding protein
Prior art date
Application number
PCT/US2001/010462
Other languages
English (en)
Other versions
WO2001075064A2 (fr
Inventor
Victoria Yamazaki
Vinod Asundi
Radoje T Drmanac
Chenghua Liu
Y Tom Tang
Original Assignee
Hyseq Inc
Victoria Yamazaki
Vinod Asundi
Radoje T Drmanac
Chenghua Liu
Y Tom Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Victoria Yamazaki, Vinod Asundi, Radoje T Drmanac, Chenghua Liu, Y Tom Tang filed Critical Hyseq Inc
Priority to AU2001255214A priority Critical patent/AU2001255214B2/en
Priority to AU5521401A priority patent/AU5521401A/xx
Priority to EP01928344A priority patent/EP1268510A4/fr
Priority to CA002404501A priority patent/CA2404501A1/fr
Priority to JP2001572939A priority patent/JP2004500120A/ja
Publication of WO2001075064A2 publication Critical patent/WO2001075064A2/fr
Publication of WO2001075064A3 publication Critical patent/WO2001075064A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne de nouveaux polynucléotides, et des polypeptides codés par ces polynucléotides et des mutants ou variants desdits polynucléotides, qui correspondent aux nouveaux polypeptides humains sécrétés semblables à la protéine de liaison au facteur de croissance semblable à l'insuline (IGFBP). Ces polynucléotides comprennent des séquences d'acide nucléique isolées d'une bibliothèque d'ADNc issue de l'ARNm de la glande surrénale (Clontech) (SEQ ID NO. 1) et de l'ARNm du thymus (Clontech) (SEQ ID NO. 2). D'autres aspects de l'invention incluent des processus contenant des vecteurs servant à produire de nouveaux polypeptides humains sécrétés semblables à l'IGFBP et des anticorps spécifiques desdits polypeptides.
PCT/US2001/010462 2000-03-31 2001-03-30 Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline WO2001075064A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001255214A AU2001255214B2 (en) 2000-03-31 2001-03-30 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
AU5521401A AU5521401A (en) 2000-03-31 2001-03-30 Method and materials relating to insulin-like growth factor binding protein-likepolypeptides and polynucleotides
EP01928344A EP1268510A4 (fr) 2000-03-31 2001-03-30 Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline
CA002404501A CA2404501A1 (fr) 2000-03-31 2001-03-30 Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline
JP2001572939A JP2004500120A (ja) 2000-03-31 2001-03-30 インスリン様増殖因子結合タンパク質様ポリペプチドおよびポリヌクレオチドに関する方法と材料

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54021700A 2000-03-31 2000-03-31
US09/540,217 2000-03-31
US64916700A 2000-08-23 2000-08-23
US09/649,167 2000-08-23
US78474801A 2001-02-14 2001-02-14
US09/784,748 2001-02-14

Publications (2)

Publication Number Publication Date
WO2001075064A2 WO2001075064A2 (fr) 2001-10-11
WO2001075064A3 true WO2001075064A3 (fr) 2002-02-28

Family

ID=27415319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010462 WO2001075064A2 (fr) 2000-03-31 2001-03-30 Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline

Country Status (5)

Country Link
EP (1) EP1268510A4 (fr)
JP (1) JP2004500120A (fr)
AU (2) AU2001255214B2 (fr)
CA (1) CA2404501A1 (fr)
WO (1) WO2001075064A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081515A1 (fr) * 2001-04-03 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Proteine de liaison de facteur de croissance de type insuline
EP2316922B1 (fr) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Anticorps anti-IGFR humain neutralisant
CA2541015A1 (fr) 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001094416A2 (fr) * 2000-06-07 2001-12-13 Curagen Corporation Nouvelles proteines et acides nucleiques qui les codent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 7 August 1997 (1997-08-07), FUJIMOTO N.: "Cloning of a gene specifically expressed in the neurostem cell and developing central nervous system", XP002949664 *
See also references of EP1268510A4 *

Also Published As

Publication number Publication date
EP1268510A2 (fr) 2003-01-02
EP1268510A4 (fr) 2003-05-28
AU2001255214B2 (en) 2006-06-08
CA2404501A1 (fr) 2001-10-11
AU5521401A (en) 2001-10-15
WO2001075064A2 (fr) 2001-10-11
JP2004500120A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
WO2001088092A3 (fr) Procedes et materiaux relatifs aux polypeptides et polynucleotides du type facteur des cellules souches (du type fcs)
EP1308459A3 (fr) Séquences d'ADN complementaires pleine longueur
CA2343715A1 (fr) Sequence codante pour un nouveau facteur de differenciation de la croissance d'origine humaine et polypeptide code par cette sequence d'adn, et methode de production correspondante
EP1440981A3 (fr) ADN complementaire humaine de pleine longueur
WO2001055336A3 (fr) Procedes et substances relatifs a des polypeptides de type cd84 et a des polynucleotides
WO2003048202A3 (fr) Gène activant le facteur nucléaire kappa b
WO2001053454A3 (fr) Procedes et elements ayant trait a des polypeptides et des polynucleotides de type recepteurs couples a une proteine g
WO2001077169A3 (fr) Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides du type facteur de croissance des cellules-souches
CA2343569A1 (fr) Facteur de croissance transformant beta - 9 mammaliens
WO2001075064A3 (fr) Methode et materiels relatifs a des polypeptides et a des polynucleotides semblables a la proteine de liaison au facteur de croissance semblable a l'insuline
WO2001055335A3 (fr) Procedes et materiaux se rapportant a des polypeptides et polynucleotides semblables a des recepteurs de leucocytes de type immunoglobuline (lir)
EP1574520A3 (fr) Polypeptides et polynucléotides ressemblant à la molécule de guidage neuronale ainsi que méthodes et matériaux dérivés
WO1997031111A3 (fr) Famille de transporteurs d'anions organiques, acides nucleiques codant ceux-ci, cellules les comprenant et procedes d'utilisation associes
WO2001053500A8 (fr) Procedes et substances relatifs a des polypeptides de type facteur de croissance de cellules souches et a des polynucleotides
WO2001053456A8 (fr) Procedes et substances relatifs a des polypeptides de type prothrombinase et a des polynucleotides
WO2001055337A3 (fr) Procedes et substances relatifs a des polypeptides de type antigene carcino-embryonnaire (cea) et a des polynucleotides
WO2001055435A3 (fr) Methodes et materiaux associes a des polypeptides et des polynucleotides du type cytokine hematopoietique
WO2001055332A3 (fr) Methodes et materiaux relatifs a de nouveaux polypeptides et polynucleotides de type regulateur de croissance
WO2003040326A3 (fr) Polypeptides et polynucleotides de type prokineticine, procedes et materiaux associes
Huang et al. Isolation and sequence of cDNA encoding the motilin precursor from monkey intestine. Demonstration of the motilin precursor in the monkey brain
EP0801133A3 (fr) Lyases de hydroxy-peroxyde
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
WO2001057233A3 (fr) Methodes et materiaux associes a des polypeptides et des polynucleotides du type facteur-1 des preadipocytes (du type pref-1)
WO2001057175A3 (fr) Procedes et materiaux concernant des polypeptides et des polynucleotides du type neurotrimin
WO1997040069A3 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2404501

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572939

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001928344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001255214

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001928344

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载